Taming glutamate excitotoxicity: Strategic pathway modulation for neuroprotection

CNS Drugs

Volumn 29, Issue 2, 2015, Pages 153-162

  Jia, Ming ^a   Njapo, Steve A Noutong ^a   Rastogi, Vaibhav ^a   Hedna, Vishnumurthy Shushrutha ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; EBSELEN; FREE RADICAL; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NITRIC OXIDE SYNTHASE; NORPHENAZONE; SCAVENGER;

BLOOD BRAIN BARRIER; EXCITOTOXICITY; HUMAN; INHIBITION KINETICS; MEDICAL LITERATURE; MOLECULAR MECHANICS; NERVE CELL DEGENERATION; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL DEATH; DRUG EFFECTS; NERVE CELL; PHYSIOLOGY;

ANIMALS; CELL DEATH; GLUTAMIC ACID; HUMANS; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 84925487809     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0225-3     Document Type: Review

References (89)

1. Teichberg V, Cohen-Kashi-Malina K, Cooper I, Zlotnik A. Homeostasis of glutamate in brain fluids: an accelerated brain-to-blood efflux of excess glutamate is produced by blood glutamate scavenging and offers protection from neuropathologies. Neuroscience. 2009;158(1):301-8.
2. Zauner A, Bullock R, Kuta AJ, Woodward J, Young HF. Glutamate release and cerebral blood flow after severe human head injury. Acta Neurochir Suppl. 1996;67:40-4.
3. Shaw P, Forrest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration. 1995;4:209-16.
4. Spranger M, Krempien S, Schwab S, Maiwald M, Bruno K, Hacke W. Excess glutamate in the cerebrospinal fluid in bacterial meningitis. J Neurol Sci. 1996;143:126-31.
5. Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):101-5.
6. Sattler R, Tymianski M. Molecular mechanisms of calcium-dependent excitotoxicity. J Mol Med (Berl). 2000;78(1):3-13.
7. Muir K. Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists. Curr Opin Pharmacol. 2006;6(1):53-60.
8. Benveniste H, Jørgensen MB, Diemer NH, Hansen AJ. Calcium accumulation by glutamate receptor activation is involved in hippocampal cell damage after ischemia. Acta Neurol Scand. 1988;78(6):529-36.
9. Manev H, Favaron M, Guidotti A, Costa E. Delayed increase of Ca2+ influx elicited by glutamate: role in neuronal death. Mol Pharmacol. 1989;36(1):106-12.
10. Castillo M, Babson J. Ca2-dependent mechanisms of cell injury in cultured cortical neurons. Neuroscience. 1998;86(4):1133-44.
11. Li S, Stys P. Na(+)-K(+)-ATPase inhibition and depolarization induce glutamate release via reverse NA(+)-dependent transport in spinal cord white matter. Neuroscience. 2001;107(4):675-83.
12. Ikonomidou C, Turski L. Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol. 2002;1(6):383-6.
13. Stoica BA, Faden AI. Cell death mechanisms and modulation in traumatic brain injury. Neurotherapeutics. 2010;7(1):3-12.
14. Yuan J, Lipinski M, Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron. 2003;40(2):401-13.
15. Leibowitz A, Boyko M, Shapira Y, Zlotnik A. Blood glutamate scavenging: insight into neuroprotection. Int J Mol Sci. 2012;13(12):10041-66.
16. Castillo J, Davalos A, Naveiro J, Noya M. Neuroexcitatory amino acids and their relation to infarct size and neurological deficit in ischemic stroke. Stroke. 1996;27(6):1060-5.
17. Zlotnik A, Sinelnikov I, Gruenbaum BF, Gruenbaum SE, Dubilet M, Dubilet E, et al. Effect of glutamate and blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome and pathohistology of the hippocampus after traumatic brain injury in rats. Anesthesiology. 2012;116(1):73-83.
18. Andreadou E, Kapaki E, Kokotis P, Paraskevas GP, Katsaros N, Libitaki G, et al. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment. Clin Neurol Neurosurg. 2008;110(3):222-6.
19. Stojanovic IR, Kostic M, Ljubisavljevic S. The role of glutamate and its receptors in multiple sclerosis. J Neural Transm. 2014;121(8):945-55.
20. Hawkins RA, Mokashi A, Dejoseph MR, Viña JR, Fernstrom JD. Glutamate permeability at the blood-brain barrier in insulinopenic and insulin-resistant rats. Metabolism. 2010;59(2):258-66.
21. O'kane RL. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier: a mechanism for glutamate removal. J Biol Chem. 1999;274(45):31891-5.
22. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature. 2000;407(6767):316-21.
23. Caldeira MV, Salazar IL, Curcio M, Canzoniero LM, Duarte CB. Role of the ubiquitin-proteasome system in brain ischemia: friend or foe? Prog Neurobiol. 2014;112:50-69.
24. Parsons MP, Raymond LA. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron. 2014;82(2):279-93.
25. Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010;460(2):525-42.
26. Boyko M, Melamed I, Gruenbaum BF, Gruenbaum SE, Ohayon S, Leibowitz A, et al. The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage. Neurotherapeutics. 2012;9(3):649-57.
27. Campos F, Sobrino T, Perez-Mato M, Rodriguez-Osorio X, Leira R, Blanco M, et al. Glutamate oxaloacetate transaminase: a new key in the dysregulation of glutamate in migraine patients. Cephalalgia. 2013;33(14):1148-54.
28. Zlotnik A, Gurevich B, Cherniavsky E, Tkachov S, Ruban AM, Leon A, et al. The contribution of the blood glutamate scavenging activity of pyruvate to its neuroprotective properties in a rat model of closed head injury. Neurochem Res. 2008;33(6):1044-50.
29. Van Den Tweel E, Van Bel F, Kavelaars A, Peeters-Scholte C, Haumann J, Nijboer CHA, et al. Long-term neuroprotection with 2-iminobiotin, an inhibitor of neuronal and inducible nitric oxide synthase, after cerebral hypoxia-ischemia in neonatal rats. J Cereb Blood Flow Metab. 2005;25(1):67-74.
30. Aarts M. Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions. Science. 2002;298(5594):846-50.
31. Jones N. Stroke: disruption of the NNOS-PSD-95 complex is neuroprotective in models of cerebral ischemia. Nat Rev Neurol. 2011;7(2):61.
32. Zhou L, Li F, Xu H-B, Luo C-X, Wu H-Y, Zhu M-M, et al. Treatment of cerebral ischemia by disrupting ischemia-induced interaction of NNOS with PSD-95. Nat Med. 2010;16(12):1439-43.
33. Boyko M, Gruenbaum SE, Gruenbaum BR, Shipira Y, Zlotnik A. Brain to blood glutamate scavenging as a novel therapeutic modality: a review. J Neural Transm. 2014;121(8):971-9.
34. Lee J-M, Zipfel GJ, Choi DW. The changing landscape of ischaemic brain injury mechanisms. Nature. 1999;399:A7-14.
35. Dykens JA. Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA2+ and NA+: implications for neurodegeneration. J Neurochem. 1994;63(2):584-91.
36. Ogden KK, Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci. 2011;32(12):726-33.
37. Kalia LV, Kalia SK, Salter MW. NMDA receptors in clinical neurology: excitatory times ahead. Lancet Neurol. 2008;7(8):742-55.
38. Lipton SA. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx. 2004;1(1):101-10.
39. Decker H, Jürgensen S, Adrover MF, Brito-Moreira J, Bomfim TR, Klein WL, et al. N-methyl-d-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J Neurochem. 2010;115(6):1520-9.
40. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem. 2007;282(15):11590-601.
41. Gottlieb M, Wang Y, Teichberg VI. Blood-mediated scavenging of cerebrospinal fluid glutamate. J Neurochem. 2003;87(1):119-26.
42. Zlotnik A, Gurevich B, Tkachov S, Maoz I, Shapira Y, Teichberg VI. Brain neuroprotection by scavenging blood glutamate. Exp Neurol. 2007;203(1):213-20.
43. Zlotnik A, Gruenbaum SE, Artru AA, Rozet I, Dubilet M, Tkachov S, et al. The neuroprotective effects of oxaloacetate in closed head injury in rats is mediated by its blood glutamate scavenging activity. J Neurosurg Anesthesiol. 2009;21(3):235-41.
44. Baker AJ, Moulton RJ, Macmillan VH, Shedden PM. Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans. J Neurosurg. 1993;79(3):369-72.
45. Palmer AM, Marion DW, Botscheller ML, Swedlow PE, Styren SD, Dekosky ST. Traumatic brain injury-induced excitotoxicity assessed in a controlled cortical impact model. J Neurochem. 1993;61(6):2015-24.
46. Castillo J, Dávalos A, Noya M. Progression of ischaemic stroke and excitotoxic aminoacids. Lancet. 1997;349(9045):79-83.
47. Campos F, Sobrino T, Ramos-Cabrer P, Argibay B, Agulla J, Pérez-Mato M, et al. Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab. 2011;31(6):1378-86.
48. Nagy D, Marosi M, Kis Z, Farkas T, Rakos G, Vecsei L, et al. Oxaloacetate decreases the infarct size and attenuates the reduction in evoked responses after photothrombotic focal ischemia in the rat cortex. Cell Mol Neurobiol. 2009;26(6):827-35.
49. Pérez-Mato M, Ramos-Cabrer P, Sobrino T, Blanco M, Ruban A, Mirelman D, et al. Human recombinant glutamate oxaloacetate transaminase 1 (GOT1) supplemented with oxaloacetate induces a protective effect after cerebral ischemia. Cell Death Dis. 2014;5(1):e992.
50. Boyko M, Zlotnik A, Gruenbaum BF, Gruenbaum SE, Ohayon S, Kuts R, et al. Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke. Eur J Neurosci. 2011;34(9):1432-41.
51. Knapp L, Gellért L, Kocsis K, Kis Z, Farkas T, Vécsei L, et al. Neuroprotective effect of oxaloacetate in a focal brain ischemic model in the rat. Cell Mol Neurobiol (Epub 8 May 2014).
52. Carvalho A, Rodrigues S, Torres LB, Persike DS, Fernandes MJS, Amado D, et al. Neuroprotective effect of pyruvate and oxaloacetate during pilocarpine induced status epilepticus in rats. Neurochem Int. 2011;58(3):385-90.
53. Tattersall J. Seizure activity post organophosphate exposure. Front Biosci (Landmark Ed). 2009;14:3688-711.
54. Ruban A, Mohar B, Jona G, Teichberg VI. Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication. J Cereb Blood Flow Metab. 2014;34(2):221-7.
55. Rogachev B, Tsesis S, Gruenbaum BF, Gruenbaum SE, Boyko M, Klein M, et al. The effects of peritoneal dialysis on blood glutamate levels: implementation for neuroprotection. J Neurosurg Anesthesiol. 2013;25(3):262-6.
56. Godino MeC, Romera VG, Sánchez-Tomero JA, Pacheco J, Canals S, Lerma J, et al. Amelioration of ischemic brain damage by peritoneal dialysis. J Clin Invest. 2013;123(10):4359-63.
57. Srinivasan K, Sharma SS. 3-Bromo-7-nitroindazole attenuates brain ischemic injury in diabetic stroke via inhibition of endoplasmic reticulum stress pathway involving CHOP. Life Sci. 2012;90(3):154-60.
58. Yin X-H, Yan J-Z, Hou X-Y, Wu S-L, Zhang G-Y. Neuroprotection of S-nitrosoglutathione against ischemic injury by down-regulating Fas S-nitrosylation and downstream signaling. Neuroscience. 2013;248:290-8.
59. Lu A, Wagner KR, Broderick JP, Clark JF. Administration of S-methyl-l-thiocitrulline protects against brain injuries after intracerebral hemorrhage. Neuroscience. 2014;270:40-7.
60. Cook DJ, Teves L, Tymianski M. Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012;483(7388):213-7.
61. Lai TW, Zhang S, Wang YT. Excitotoxicity and stroke: identifying novel targets for neuroprotection. Prog Neurobiol. 2014;115:157-88.
62. Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C. Neuroprotection for stroke: current status and future perspectives. Int J Mol Sci. 2012;13(12):11753-72.
63. Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11(10):1753-63.
64. Fan J, Long H, Li Y, Liu Y, Zhou W, Li Q, et al. Edaravone protects against glutamate-induced PERK/EIF2α/ATF4 integrated stress response and activation of caspase-12. Brain Res. 2013;1519:1-8.
65. Feng S, Yang Q, Liu M, Li W, Yuan W, Zhang S, et al. Edaravone for acute ischaemic stroke. Cochrane Database Syst Rev. 2011;(12):CD007230.
66. Yang J, Liu M, Zhou J, Zhang S, Lin S, Zhao H. Edaravone for acute intracerebral haemorrhage. Cochrane Database Syst Rev. 2011;(2):CD007755.
67. Otomo E. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15(3):222-9.
68. Inatomi Y, Takita T, Yonehara T, Fujioka S, Hashimoto Y, Hirano T, et al. Efficacy of edaravone in cardioembolic stroke. Int Med. 2006;45(5):253-7.
69. Mishina M, Komaba Y, Kobayashi S, Tanaka N, Kominami S, Fukuchi T, et al. Efficacy of edaravone, a free radical scavenger, for the treatment of acute lacunar infarction. Neurol Med Chir. 2005;45(7):344-8.
70. Ohta Y, Takamatsu K, Fukushima T, Ikegami S, Takeda I, Ota T, et al. Efficacy of the free radical scavenger, edaravone, for motor palsy of acute lacunar infarction. Int Med. 2009;48(8):593-6.
71. Abe M, Kaizu K, Matsumoto K. A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. Ther Apher Dial. 2007;11(3):235-40.
72. Hishida A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exper Nephrol. 2007;11(4):292-6.
73. Kano T, Harada T, Hirayama T, Katayama Y. Combination therapy using TPA and edaravone improves the neurotoxic effect of TPA. Interv Neuroradiol. 2007;13:106-8.
74. Parnham MJ, Sies H. The early research and development of ebselen. Biochem Pharmacol. 2013;86(9):1248-53.
75. Seo JY, Lee CH, Cho JH, Choi JH, Yoo K-Y, Kim DW, et al. Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. J Neurol Sci. 2009;285(1):88-94.
76. Kalayci M, Coskun O, Cagavi F, Kanter M, Armutcu F, Gul S, et al. Neuroprotective effects of ebselen on experimental spinal cord injury in rats. Neurochem Res. 2005;30(3):403-10.
77. Koizumi H, Fujisawa H, Suehiro E, Shirao S, Suzuki M. Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. Neurol Med Chir. 2011;51(5):337-43.
78. Mazzanti CM, Spanevello R, Ahmed M, Pereira LB, Gonçalves JF, Corrêa M, et al. Pre-treatment with ebselen and vitamin E modulate acetylcholinesterase activity: interaction with demyelinating agents. Int J Dev Neurosci. 2009;27(1):73-80.
79. Porciúncula LO, Rocha JBT, Boeck CR, Vendite D, Souza DO. Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons. Neurosci Lett. 2001;299(3):217-20.
80. Yamaguchi T, Sano K, Takakura K, Saito I, Shinohara Y, Asano T, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke. 1998;29(1):12-7.
81. Ogawa A, Yoshimoto T, Kikuchi H, Sano K, Saito I, Yamaguchi T, et al. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis. 1999;9(2):112-8.
82. Mason RP, Casu M, Butler N, Breda C, Campesan S, Clapp J, et al. Glutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat Genet. 2013;45(10):1249-54.
83. Wei L, Zhang Y, Yang C, Wang Q, Zhuang Z, Sun Z. Neuroprotective effects of ebselen in traumatic brain injury model: involvement of nitric oxide and P38 mitogen-activated protein kinase signalling pathway. Clin Exp Pharmacol Physiol. 2014;41(2):134-8.
84. Wu J, Li Q, Wang X, Yu S, Li L, Wu X, et al. Neuroprotection by curcumin in ischemic brain injury involves the Akt/Nrf2 pathway. PLoS One. 2013;8(3):e59843.
85. Kuo C-P, Lu C-H, Wen L-L, Cherng C-H, Wong C-S, Borel CO, et al. Neuroprotective effect of curcumin in an experimental rat model of subarachnoid hemorrhage. Anesthesiology. 2011;115(6):1229-38.
86. Tu XK, Yang WZ, Chen JP, Chen Y, Ouyang LQ, Xu YC, et al. Curcumin inhibits TLR2/4-NF-κB signaling pathway and attenuates brain damage in permanent focal cerebral ischemia in rats. Inflammation. 2014;37(5):1544-51.
87. Koh P-O. Ferulic acid attenuates the injury-induced decrease of protein phosphatase 2A subunit B in ischemic brain injury. PLoS One. 2013;8(1):e54217.
88. Ballaz S, Morales I, Rodríguez M, Obeso JA. Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons. J Neurosci Res. 2013;91(12):1609-17.
89. Katnik C, Cuevas J. Non-specific inhibition of ischemia- and acidosis-induced intracellular calcium elevations and membrane currents by α-phenyl-N-tert-butylnitrone, butylated hydroxytoluene and trolox. Int J Mol Sci. 2014;15(3):3596-611.